Article
Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma.
Blood advances - 13 Aug 2024
Ramirez Cody A, Becker-Hapak Michelle, Singhal Kartik, Russler-Germain David A, Frenkel Felix, Barnell Erica K, McClain Ethan D, Desai Sweta, Schappe Timothy, Onyeador Onyinyechi C, Kudryashova Olga, Belousov Vladislav, Bagaev Alexander, Ocheredko Elena, Kiwala Susanna, Hundal Jasreet, Skidmore Zachary L, Watkins Marcus P, Mooney Thomas B, Walker Jason R, Krysiak Kilannin, Gomez Felicia, Fronick Catrina C, Fulton Robert S, Schreiber Robert D, Mehta-Shah Neha, Cashen Amanda F, Kahl Brad S, Ataullakhanov Ravshan, Bartlett Nancy L, Griffith Malachi, Griffith Obi L, Fehniger Todd A
Abstract excerpt
ABSTRACT: Personalized cancer vaccines designed to target neoantigens represent a promising new treatment paradigm in oncology. In contrast to classical idiotype vaccines, we hypothesized that "polyvalent" vaccines could be engineered for the personalized treatment of follicular lymphoma (FL) using neoantigen discovery by combined whole-exome sequencing (WES) and RNA sequencing (RNA-seq). Fifty-eight tumor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.